Terumo

Founded in 2018 and based in Redwood City, California, Bone Health Technologies designs and manufactures OsteoBoost, a wearable medical device that uses whole-body vibration technology to provide weight-bearing exercise and mechanical stimulation to the hips and spine. Clinically proven to slow bone density loss in postmenopausal women with osteopenia, OsteoBoost offers a convenient, non-pharmacological, pain-free treatment option for nearly 64 million Americans at risk of osteoporotic fractures.

Sequent Medical is a privately-held medical device company focused on developing innovative catheter-based neurovascular technologies. Founded in 2006, the company is headquartered in Aliso Viejo, California, with additional operations in Bonn, Germany. Sequent Medical has invented and developed Microbraid technology to create the WEB Aneurysm Embolization System, a versatile treatment option for both ruptured and unruptured intracranial aneurysms. The WEB system has received CE mark approval and has been used to treat nearly 600 aneurysms in Europe, Latin America, and New Zealand. However, it is not available for sale or use in the United States.

MicroVention Terumo is a medical device company headquartered in Tustin, California, specializing in catheter-based and minimally invasive neuroendovascular technologies aimed at treating cerebral aneurysms and other neurovascular diseases. Founded in 1997, it operates as a subsidiary of Terumo Corporation. The company develops a range of products, including delivery and detachment systems, access products, intraluminal devices, occlusion balloons, and flow diverters. Notably, MicroVention Terumo offers advanced embolization solutions such as the HydroCoil Embolic System, which utilizes platinum micro-coil technology, and the MicroPlex Coil System, which features a combination of framing, helical filling, and finishing coils to effectively address various types of aneurysm morphologies. Its products are distributed through a network of specialty distributors across North America, South America, Europe, Africa, the Middle East, and Asia Pacific, contributing to improved patient outcomes in the treatment of vascular conditions.